C
Cavion
Clinical stage pharmaceutical company committed to providing patients with therapies
About Cavion
Cavion is a clinical-stage pharmaceutical company focused on developing innovative therapies to address neurological and rare genetic diseases. The company specializes in modulating overactive T-type calcium channels, known as Cav3, to restore natural rhythms in patients' bodies. Cavion's pipeline includes best-in-class Cav3 modulators, sourced from both internal drug discovery and in-licensing efforts. The company serves patients suffering from movement disorders and other neurological conditions, aiming to significantly improve their quality of life. Operating in the biopharmaceutical market, Cavion employs a business model centered around clinical research and development, leveraging its deep understanding of Cav3 biology and superior chemistry. Revenue is generated through the development and eventual commercialization of these therapies, as well as potential partnerships and licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2003
- Headquarters
- Charlottesville, United States
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Cavion is 370 monthly website visits, down 66.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CIT GAP Funds
Series A2 investors entered at this stage
Novartis Venture Fund- EVEnso Ventures
Series B and later1 investor entered at this stage
Lilly Ventures
Other known investors2 additional known investors
Jazz Pharmaceuticals
University of Virginia Seed Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cavion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cavion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.